Atovaquone and Proguanil Hydrochloride Pediatric Tablets are a fixed-dose combination of the antimalarial agents Atovaquone and Proguanil hydrochloride. The chemical name of atovaquone is trans-2-[4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthalenedione. Atovaquone is a yellow crystalline solid that is practically insoluble in water. It has a molecular weight of 366.84 and the molecular formula C22H19ClO3. The compound has the following structural formula:
The chemical name of proguanil hydrochloride is 1-(4-chlorophenyl)-5-isopropyl-biguanide hydrochloride. Proguanil hydrochloride is a white crystalline solid that is sparingly soluble in water. It has a molecular weight of 290.22 and the molecular formula C11H16ClN5•HCl. The compound has the following structural formula:
Atovaquone and Proguanil Hydrochloride Pediatric Tablets are for oral administration. Each Atovaquone and Proguanil Hydrochloride Pediatric Tablet contains 62.5 mg of atovaquone and 25 mg of proguanil hydrochloride. The inactive ingredients are low-substituted hydroxypropyl cellulose, magnesium stearate, microcrystalline cellulose, poloxamer 188, povidone K30, and sodium starch glycolate. The tablet coating contains hypromellose, polyethylene glycol 400, polyethylene glycol 8000, red iron oxide, and titanium dioxide.
Atovaquone and Proguanil - Clinical Pharmacology
Microbiology
Mechanism of ActionAtovaquone and Proguanil hydrochloride interfere with 2 different pathways involved in the biosynthesis of pyrimidines required for nucleic acid replication. Atovaquone is a selective inhibitor of parasite mitochondrial electron transport. Proguanil hydrochloride primarily exerts its effect by means of the metabolite cycloguanil, a dihydrofolate reductase inhibitor. Inhibition of dihydrofolate reductase in the malaria parasite disrupts deoxythymidylate synthesis.
Activity In Vitro and In VivoAtovaquone and cycloguanil (an active metabolite of proguanil) are active against the erythrocytic and exoerythrocytic stages of Plasmodium spp. Enhanced efficacy of the combination compared to either atovaquone or proguanil hydrochloride alone was demonstrated in clinical studies in both immune and non-immune patients (see CLINICAL STUDIES).
Drug ResistanceStrains of P. falciparum with decreased susceptibility to atovaquone or proguanil/cycloguanil alone can be selected in vitro or in vivo. The combination of Atovaquone and Proguanil hydrochloride may not be effective for treatment of recrudescent malaria that develops after prior therapy with the combination.
Pharmacokinetics
AbsorptionAtovaquone is a highly lipophilic compound with low aqueous solubility. The bioavailability of atovaquone shows considerable inter-individual variability.
Dietary fat taken with atovaquone increases the rate and extent of absorption, increasing AUC 2 to 3 times and Cmax 5 times over fasting. The absolute bioavailability of the tablet formulation of atovaquone when taken with food is 23%. Atovaquone and Proguanil hydrochloride tablets should be taken with food or a milky drink.
Proguanil hydrochloride is extensively absorbed regardless of food intake.
DistributionAtovaquone is highly protein bound (>99%) over the concentration range of 1 to 90 mcg/mL. A population pharmacokinetic analysis demonstrated that the apparent volume of distribution of atovaquone (V/F) in adult and pediatric patients after oral administration is approximately 8.8 L/kg.
Proguanil is 75% protein bound. A population pharmacokinetic analysis demonstrated that the apparent V/F of proguanil in adult and pediatric patients >15 years of age with body weights from 31 to 110 kg ranged from 1,617 to 2,502 L. In pediatric patients ≤15 years of age with body weights from 11 to 56 kg, the V/F of proguanil ranged from 462 to 966 L.
In human plasma, the binding of Atovaquone and Proguanil was unaffected by the presence of the other.
MetabolismIn a study where 14C-labeled atovaquone was administered to healthy volunteers, greater than 94% of the dose was recovered as unchanged atovaquone in the feces over 21 days. There was little or no excretion of atovaquone in the urine (less than 0.6%). There is indirect evidence that atovaquone may undergo limited metabolism; however, a specific metabolite has not been identified. Between 40% to 60% of proguanil is excreted by the kidneys. Proguanil is metabolized to cycloguanil (primarily via CYP2C19) and 4-chlorophenylbiguanide. The main routes of elimination are hepatic biotransformation and renal excretion.
EliminationThe elimination half-life of atovaquone is about 2 to 3 days in adult patients.
The elimination half-life of proguanil is 12 to 21 hours in both adult patients and pediatric patients, but may be longer in individuals who are slow metabolizers.
A population pharmacokinetic analysis in adult and pediatric patients showed that the apparent clearance (CL/F) of both Atovaquone and Proguanil are related to the body weight. The values CL/F for both Atovaquone and Proguanil in subjects with body weight ≥11 kg are shown in Table 1.
Table 1. Apparent Clearance for Atovaquone and Proguanil in Patients as a Function of Body Weight
Body Weight
|
Atovaquone
|
Proguanil
|
N
|
CL/F (L/hr)
Mean ± SDa (range)
|
N
|
CL/F (L/hr)
Mean ± SDa (range)
|
|
11-20 kg
|
159
|
1.34 ± 0.63
(0.52-4.26)
|
146
|
29.5 ± 6.5
(10.3-48.3)
|
21-30 kg
|
117
|
1.87 ± 0.81
(0.52-5.38)
|
113
|
40.0 ± 7.5
(15.9-62.7)
|
31-40 kg
|
95
|
2.76 ± 2.07
(0.97-12.5)
|
91
|
49.5 ± 8.30
(25.8-71.5)
|
>40 kg
|
368
|
6.61 ± 3.92
(1.32-20.3)
|
282
|
67.9 ± 19.9
(14.0-145)
|
a SD = standard deviation.
The pharmacokinetics of Atovaquone and Proguanil in patients with body weight below 11 kg have not been adequately characterized.
Special Populations
PediatricsThe pharmacokinetics of proguanil and cycloguanil are similar in adult patients and pediatric patients. However, the elimination half-life of atovaquone is shorter in pediatric patients (1 to 2 days) than in adult patients (2 to 3 days). In clinical trials, plasma trough levels of Atovaquone and Proguanil in pediatric patients weighing 5 to 40 kg were within the range observed in adults after dosing by body weight.
GeriatricsIn a single-dose study, the pharmacokinetics of atovaquone, proguanil, and cycloguanil were compared in 13 elderly subjects (age 65 to 79 years) to 13 younger subjects (age 30 to 45 years). In the elderly subjects, the extent of systemic exposure (AUC) of cycloguanil was increased (point estimate = 2.36, CI = 1.70, 3.28). Tmax was longer in elderly subjects (median 8 hours) compared with younger subjects (median 4 hours) and average elimination half-life was longer in elderly subjects (mean 14.9 hours) compared with younger subjects (mean 8.3 hours).
Hepatic ImpairmentIn a single-dose study, the pharmacokinetics of atovaquone, proguanil, and cycloguanil were compared in 13 subjects with hepatic impairment (9 mild, 4 moderate, as indicated by the Child-Pugh method) to 13 subjects with normal hepatic function. In subjects with mild or moderate hepatic impairment as compared to healthy subjects, there were no marked differences (<50%) in the rate or extent of systemic exposure of atovaquone. However, in subjects with moderate hepatic impairment, the elimination half-life of atovaquone was increased (point estimate = 1.28, 90% CI = 1.00 to 1.63). Proguanil AUC, Cmax, and its t1/2 increased in subjects with mild hepatic impairment when compared to healthy subjects (Table 2). Also, the proguanil AUC and its t1/2 increased in subjects with moderate hepatic impairment when compared to healthy subjects. Consistent with the increase in proguanil AUC, there were marked decreases in the systemic exposure of cycloguanil (Cmax and AUC) and an increase in its elimination half-life in subjects with mild hepatic impairment when compared to healthy volunteers (Table 2). There were few measurable cycloguanil concentrations in subjects with moderate hepatic impairment (see DOSAGE AND ADMINISTRATION). The pharmacokinetics of atovaquone, proguanil, and cycloguanil after administration of Atovaquone and Proguanil have not been studied in patients with severe hepatic impairment.
Table 2. Point Estimates (90% CI) for Proguanil and Cycloguanil Parameters in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Volunteers
Parameter
|
Comparison
|
Proguanil
|
Cycloguanil
|
AUC(0-inf)a
|
mild:healthy
|
1.96 (1.51, 2.54)
|
0.32 (0.22, 0.45)
|
Cmaxa
|
mild:healthy
|
1.41 (1.16, 1.71)
|
0.35 (0.24, 0.50)
|
t1/2b
|
mild:healthy
|
1.21 (0.92, 1.60)
|
0.86 (0.49, 1.48)
|
AUC(0-inf)a
|
moderate:healthy
|
1.64 (1.14, 2.34)
|
ND
|
Cmaxa
|
moderate:healthy
|
0.97 (0.69, 1.36)
|
ND
|
t1/2b
|
moderate:healthy
|
1.46 (1.05, 2.05)
|
ND
|
ND = not determined due to lack of quantifiable data.
a Ratio of geometric means.
b Mean difference.
Renal ImpairmentIn patients with mild renal impairment (creatinine clearance 50 to 80 mL/min), oral clearance and/or AUC data for atovaquone, proguanil, and cycloguanil are within the range of values observed in patients with normal renal function (creatinine clearance >80 mL/min). In patients with moderate renal impairment (creatinine clearance 30 to 50 mL/min), mean oral clearance for proguanil was reduced by approximately 35% compared with patients with normal renal function (creatinine clearance >80 mL/min) and the oral clearance of atovaquone was comparable between patients with normal renal function and mild renal impairment. No data exist on the use of Atovaquone and Proguanil hydrochloride for long-term prophylaxis (over 2 months) in individuals with moderate renal failure. In patients with severe renal impairment (creatinine clearance <30 mL/min), atovaquone Cmax and AUC are reduced but the elimination half-lives for proguanil and cycloguanil are prolonged, with corresponding increases in AUC, resulting in the potential of drug accumulation and toxicity with repeated dosing (see CONTRAINDICATIONS).
Drug Interactions
There are no pharmacokinetic interactions between Atovaquone and Proguanil at the recommended dose.
Concomitant treatment with tetracycline has been associated with approximately a 40% reduction in plasma concentrations of atovaquone.
Concomitant treatment with metoclopramide has also been associated with decreased bioavailability of atovaquone.
Concomitant administration of rifampin or rifabutin is known to reduce atovaquone levels by approximately 50% and 34%, respectively (see PRECAUTIONS: Drug Interactions). The mechanisms of these interactions are unknown.
Concomitant administration of atovaquone (750 mg BID with food for 14 days) and indinavir (800 mg TID without food for 14 days) did not result in any change in the steady-state AUC and Cmax of indinavir but resulted in a decrease in the Ctrough of indinavir (23% decrease [90% CI 8%, 35%]). Caution should be exercised when prescribing atovaquone with indinavir due to the decrease in trough levels of indinavir.
Atovaquone is highly protein bound (>99%) but does not displace other highly protein-bound drugs in vitro, indicating significant drug interactions arising from displacement are unlikely (see PRECAUTIONS: Drug Interactions). Proguanil is metabolized primarily by CYP2C19. Potential pharmacokinetic interactions with other substrates or inhibitors of this pathway are unknown.
Indications and Usage for Atovaquone and Proguanil
Prevention of Malaria
Atovaquone and Proguanil hydrochloride tablets are indicated for the prophylaxis of P. falciparum malaria, including in areas where chloroquine resistance has been reported (see CLINICAL STUDIES).
Treatment of Malaria
Atovaquone and Proguanil hydrochloride tablets are indicated for the treatment of acute, uncomplicated P. falciparum malaria. Atovaquone and Proguanil hydrochloride tablets have been shown to be effective in regions where the drugs chloroquine, halofantrine, mefloquine, and amodiaquine may have unacceptable failure rates, presumably due to drug resistance.
Contraindications
Atovaquone and Proguanil hydrochloride is contraindicated in individuals with known hypersensitivity to atovaquone or proguanil hydrochloride or any component of the formulation. Rare cases of anaphylaxis following treatment with atovaquone/proguanil have been reported.
Atovaquone and Proguanil hydrochloride is contraindicated for prophylaxis of P. falciparum malaria in patients with severe renal impairment (creatinine clearance <30 mL/min) (see CLINICAL PHARMACOLOGY: Special Populations: Renal Impairment).
Precautions
General
Atovaquone and Proguanil hydrochloride has not been evaluated for the treatment of cerebral malaria or other severe manifestations of complicated malaria, including hyperparasitemia, pulmonary edema, or renal failure. Patients with severe malaria are not candidates for oral therapy.
Elevated liver function tests and rare cases of hepatitis have been reported with prophylactic use of Atovaquone and Proguanil hydrochloride. A single case of hepatic failure requiring liver transplantation has also been reported with prophylactic use.
Absorption of atovaquone may be reduced in patients with diarrhea or vomiting. If Atovaquone and Proguanil hydrochloride is used in patients who are vomiting (see DOSAGE AND ADMINISTRATION), parasitemia should be closely monitored and the use of an antiemetic considered. Vomiting occurred in up to 19% of pediatric patients given treatment doses of Atovaquone and Proguanil hydrochloride. In the controlled clinical trials of Atovaquone and Proguanil hydrochloride, 15.3% of adults who were treated with atovaquone/proguanil received an antiemetic drug during that part of the trial when they received atovaquone/proguanil. Of these patients, 98.3% were successfully treated. In patients with severe or persistent diarrhea or vomiting, alternative antimalarial therapy may be required.
Parasite relapse occurred commonly when P. vivax malaria was treated with Atovaquone and Proguanil hydrochloride alone.
In the event of recrudescent P. falciparum infections after treatment with Atovaquone and Proguanil hydrochloride or failure of chemoprophylaxis with Atovaquone and Proguanil hydrochloride, patients should be treated with a different blood schizonticide.
Information for Patients
Patients should be instructed:
- to take Atovaquone and Proguanil hydrochloride tablets at the same time each day with food or a milky drink.
- to take a repeat dose of Atovaquone and Proguanil hydrochloride if vomiting occurs within 1 hour after dosing.
- to take a dose as soon as possible if a dose is missed, then return to their normal dosing schedule. However, if a dose is skipped, the patient should not double the next dose.
- that rare serious adverse events such as hepatitis, severe skin reactions, neurological, and hematological events have been reported when Atovaquone and Proguanil hydrochloride was used for the prophylaxis or treatment of malaria.
- to consult a healthcare professional regarding alternative forms of prophylaxis if prophylaxis with Atovaquone and Proguanil hydrochloride is prematurely discontinued for any reason.
- that protective clothing, insect repellents, and bednets are important components of malaria prophylaxis.
- that no chemoprophylactic regimen is 100% effective; therefore, patients should seek medical attention for any febrile illness that occurs during or after return from a malaria-endemic area and inform their healthcare professional that they may have been exposed to malaria.
- that falciparum malaria carries a higher risk of death and serious complications in pregnant women than in the general population. Pregnant women anticipating travel to malarious areas should discuss the risks and benefits of such travel with their physicians (see Pregnancy section).
Drug Interactions
Concomitant treatment with tetracycline has been associated with approximately a 40% reduction in plasma concentrations of atovaquone. Parasitemia should be closely monitored in patients receiving tetracycline. While antiemetics may be indicated for patients receiving Atovaquone and Proguanil hydrochloride, metoclopramide may reduce the bioavailability of atovaquone and should be used only if other antiemetics are not available.
Concomitant administration of rifampin or rifabutin is known to reduce atovaquone levels by approximately 50% and 34%, respectively. The concomitant administration of Atovaquone and Proguanil hydrochloride and rifampin or rifabutin is not recommended.
Proguanil may potentiate the anticoagulant effect of warfarin and other coumarin-based anticoagulants. The mechanism of this potential drug interaction has not been established. Caution is advised when initiating or withdrawing malaria prophylaxis or treatment with Atovaquone and Proguanil hydrochloride in patients on continuous treatment with coumarin-based anticoagulants. When these products are administered concomitantly, suitable coagulation tests should be closely monitored.
Atovaquone is highly protein bound (>99%) but does not displace other highly protein-bound drugs in vitro, indicating significant drug interactions arising from displacement are unlikely.
Potential interactions between proguanil or cycloguanil and other drugs that are CYP2C19 substrates or inhibitors are unknown.
Carcinogenesis, Mutagenesis, Impairment of Fertility
AtovaquoneCarcinogenicity studies in rats were negative; 24-month studies in mice showed treatment-related increases in incidence of hepatocellular adenoma and hepatocellular carcinoma at all doses tested which ranged from approximately 5 to 8 times the average steady-state plasma concentrations in humans during prophylaxis of malaria. Atovaquone was negative with or without metabolic activation in the Ames Salmonella mutagenicity assay, the Mouse Lymphoma mutagenesis assay, and the Cultured Human Lymphocyte cytogenetic assay. No evidence of genotoxicity was observed in the in vivo Mouse Micronucleus assay.
ProguanilNo evidence of a carcinogenic effect was observed in 24-month studies conducted in CD-1 mice (doses up to 1.5 times the average systemic human exposure based on AUC) and in Wistar Hannover rats (doses up to 1.1 times the average systemic human exposure).
Proguanil was negative with or without metabolic activation in the Ames Salmonella mutagenicity assay and the Mouse Lymphoma mutagenesis assay. No evidence of genotoxicity was observed in the in vivo Mouse Micronucleus assay.
Cycloguanil, the active metabolite of proguanil, was also negative in the Ames test, but was positive in the Mouse Lymphoma assay and the Mouse Micronucleus assay. These positive effects with cycloguanil, a dihydrofolate reductase inhibitor, were significantly reduced or abolished with folinic acid supplementation.
A fertility study in Sprague-Dawley rats revealed no adverse effects at doses up to 16 mg/kg/day of proguanil hydrochloride (up to 0.2-times the average human exposure based on AUC comparisons.) Fertility studies of proguanil in animals at exposures similar to or greater than those observed in humans have not been conducted.
Genotoxicity studies have not been performed with atovaquone in combination with proguanil. Effects of Atovaquone and Proguanil hydrochloride on male and female reproductive performance are unknown.
Pregnancy
Pregnancy Category C. Falciparum malaria carries a higher risk of morbidity and mortality in pregnant women than in the general population. Maternal death and fetal loss are both known complications of falciparum malaria in pregnancy. In pregnant women who must travel to malaria-endemic areas, personal protection against mosquito bites should always be employed (see Information for Patients) in addition to antimalarials.
Atovaquone was not teratogenic and did not cause reproductive toxicity in rats at maternal plasma concentrations up to 5 to 6.5 times the estimated human exposure during treatment of malaria. Following single-dose administration of 14C-labeled atovaquone to pregnant rats, concentrations of radiolabel in rat fetuses were 18% (mid-gestation) and 60% (late gestation) of concurrent maternal plasma concentrations. In rabbits, atovaquone caused maternal toxicity at plasma concentrations that were approximately 0.6 to 1.3 times the estimated human exposure during treatment of malaria. Adverse fetal effects in rabbits, including decreased fetal body lengths and increased early resorptions and post-implantation losses, were observed only in the presence of maternal toxicity. Concentrations of atovaquone in rabbit fetuses averaged 30% of the concurrent maternal plasma concentrations.
A pre- and post-natal study in Sprague-Dawley rats revealed no adverse effects at doses up to 16 mg/kg/day of proguanil hydrochloride (up to 0.2-times the average human exposure based on AUC comparisons). Pre- and post-natal studies of proguanil in animals at exposures similar to or greater than those observed in humans have not been conducted.
The combination of Atovaquone and Proguanil hydrochloride was not teratogenic in rats at plasma concentrations up to 1.7 and 0.10 times, respectively, the estimated human exposure during treatment of malaria. In rabbits, the combination of Atovaquone and Proguanil hydrochloride was not teratogenic or embryotoxic to rabbit fetuses at plasma concentrations up to 0.34 and 0.82 times, respectively, the estimated human exposure during treatment of malaria.
While there are no adequate and well-controlled studies of atovaquone and/or proguanil hydrochloride in pregnant women, Atovaquone and Proguanil hydrochloride may be used if the potential benefit justifies the potential risk to the fetus. The proguanil component of Atovaquone and Proguanil hydrochloride acts by inhibiting the parasitic dihydrofolate reductase (see CLINICAL PHARMACOLOGY: Microbiology: Mechanism of Action). However, there are no clinical data indicating that folate supplementation diminishes drug efficacy, and for women of childbearing age receiving folate supplements to prevent neural tube birth defects, such supplements may be continued while taking Atovaquone and Proguanil hydrochloride.
Nursing Mothers
It is not known whether atovaquone is excreted into human milk. In a rat study, atovaquone concentrations in the milk were 30% of the concurrent atovaquone concentrations in the maternal plasma.
Proguanil is excreted into human milk in small quantities.
Caution should be exercised when Atovaquone and Proguanil hydrochloride is administered to a nursing woman.
Pediatric Use
Treatment of MalariaThe efficacy and safety of Atovaquone and Proguanil hydrochloride for the treatment of malaria have been established in controlled studies involving pediatric patients weighing 5 kg or more (see CLINICAL STUDIES). Safety and effectiveness have not been established in pediatric patients who weigh less than 5 kg.
Prophylaxis of MalariaThe efficacy and safety of Atovaquone and Proguanil hydrochloride have been established for the prophylaxis of malaria in controlled studies involving pediatric patients weighing 11 kg or more (see CLINICAL STUDIES). Safety and effectiveness have not been established in pediatric patients who weigh less than 11 kg.
Geriatric Use
Clinical studies of Atovaquone and Proguanil hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, the higher systemic exposure to cycloguanil (see CLINICAL PHARMACOLOGY: Special Populations: Geriatrics), and the greater frequency of concomitant disease or other drug therapy.
Adverse Reactions
Because Atovaquone and Proguanil hydrochloride tablets contain Atovaquone and Proguanil hydrochloride, the type and severity of adverse reactions associated with each of the compounds may be expected. The higher treatment doses of Atovaquone and Proguanil hydrochloride were less well tolerated than the lower prophylactic doses.
Among adults who received Atovaquone and Proguanil hydrochloride for treatment of malaria, attributable adverse experiences that occurred in ≥5% of patients were abdominal pain (17%), nausea (12%), vomiting (12%), headache (10%), diarrhea (8%), asthenia (8%), anorexia (5%), and dizziness (5%). Treatment was discontinued prematurely due to an adverse experience in 4 of 436 adults treated with Atovaquone and Proguanil hydrochloride.
Among pediatric patients (weighing 11 to 40 kg) who received Atovaquone and Proguanil hydrochloride for the treatment of malaria, attributable adverse experiences that occurred in ≥5% of patients were vomiting (10%) and pruritus (6%). Vomiting occurred in 43 of 319 (13%) pediatric patients who did not have symptomatic malaria but were given treatment doses of Atovaquone and Proguanil hydrochloride for 3 days in a clinical trial. The design of this clinical trial required that any patient who vomited be withdrawn from the trial. Among pediatric patients with symptomatic malaria treated with Atovaquone and Proguanil hydrochloride, treatment was discontinued prematurely due to an adverse experience in 1 of 116 (0.9%).
In a study of 100 pediatric patients (5 to <11 kg body weight) who received Atovaquone and Proguanil hydrochloride for the treatment of uncomplicated P. falciparum malaria, only diarrhea (6%) occurred in ≥5% of patients as an adverse experience attributable to Atovaquone and Proguanil hydrochloride. In 3 patients (3%), treatment was discontinued prematurely due to an adverse experience.
Abnormalities in laboratory tests reported in clinical trials were limited to elevations of transaminases in malaria patients being treated with Atovaquone and Proguanil hydrochloride. The frequency of these abnormalities varied substantially across studies of treatment and were not observed in the randomized portions of the prophylaxis trials.
In one phase III trial of malaria treatment in Thai adults, early elevations of ALT and AST were observed to occur more frequently in patients treated with Atovaquone and Proguanil hydrochloride compared to patients treated with an active control drug. Rates for patients who had normal baseline levels of these clinical laboratory parameters were: Day 7: ALT 26.7% vs. 15.6%; AST 16.9% vs. 8.6%. By day 14 of this 28-day study, the frequency of transaminase elevations equalized across the 2 groups.
In this and other studies in which transaminase elevations occurred, they were noted to persist for up to 4 weeks following treatment with Atovaquone and Proguanil hydrochloride for malaria. None were associated with untoward clinical events.
Among subjects who received Atovaquone and Proguanil hydrochloride for prophylaxis of malaria in placebo-controlled trials, adverse experiences occurred in similar proportions of subjects receiving Atovaquone and Proguanil hydrochloride or placebo (Table 3). The most commonly reported adverse experiences possibly attributable to Atovaquone and Proguanil hydrochloride or placebo were headache and abdominal pain. Prophylaxis with Atovaquone and Proguanil hydrochloride was discontinued prematurely due to a treatment-related adverse experience in 3 of 381 adults and 0 of 125 pediatric patients.
Table 3. Adverse Experiences in Placebo-Controlled Clinical Trials of Atovaquone and Proguanil Hydrochloride for Prophylaxis of Malaria
Adverse Experience
|
Percent of Subjects With Adverse Experiences
(Percent of Subjects With Adverse Experiences Attributable to Therapy)
|
Adults
|
Children and Adolescents
|
Placebo
n = 206
|
Atovaquone and Proguanil HCla
n = 206
|
Atovaquone and Proguanil HClb
n = 381
|
Placebo
n = 140
|
Atovaquone and Proguanil HCl
n = 125
|
Headache
|
27
|
(7)
|
22
|
(3)
|
17
|
(5)
|
21
|
(14)
|
19
|
(14)
|
Fever
|
13
|
(1)
|
5
|
(0)
|
3
|
(0)
|
11
|
(<1)
|
6
|
(0)
|
Myalgia
|
11
|
(0)
|
12
|
(0)
|
7
|
(0)
|
0
|
(0)
|
0
|
(0)
|
Abdominal pain
|
10
|
(5)
|
9
|
(4)
|
6
|
(3)
|
29
|
(29)
|
33
|
(31)
|
Cough
|
8
|
(<1)
|
6
|
(<1)
|
4
|
(1)
|
9
|
(0)
|
9
|
(0)
|
Diarrhea
|
8
|
(3)
|
6
|
(2)
|
4
|
(1)
|
3
|
(1)
|
2
|
(0)
|
Upper respiratory infection
|
7
|
(0)
|
8
|
(0)
|
5
|
(0)
|
0
|
(0)
|
<1
|
(0)
|
Dyspepsia
|
5
|
(4)
|
3
|
(2)
|
2
|
(1)
|
0
|
(0)
|
0
|
(0)
|
Back pain
|
4
|
(0)
|
8
|
(0)
|
4
|
(0)
|
0
|
(0)
|
0
|
(0)
|
Gastritis
|
3
|
(2)
|
3
|
(3)
|
2
|
(2)
|
0
|
(0)
|
0
|
(0)
|
Vomiting
|
2
|
(<1)
|
1
|
(<1)
|
<1
|
(<1)
|
6
|
(6)
|
7
|
(7)
|
Flu syndrome
|
1
|
(0)
|
2
|
(0)
|
4
|
(0)
|
6
|
(0)
|
9
|
(0)
|
Any adverse experience
|
65
|
(32)
|
